Skip to main content

Rhodes Jason P's Form 4 filing

Dyne Therapeutics, Inc. (DYN) · filed Feb 20, 2024

Accession no.
0001415889-24-004471
Filed
Feb 20, 2024
Trade date
Feb 15-20, 2024
Filing delay
5 days
Rule 10b5-1 plan
Checked

This filing lists 5 non-derivative transactions. Open-market sales total $11.9M. It was filed 5 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Rhodes Jason PCIK 0001577014Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Feb 15, 2024Common StockSSaleDisposed−175,793$23.88F2−$4,197,936.847,150,324Indirect
Feb 15, 2024Common StockSSaleDisposed−2,113$24.45F4−$51,662.857,148,211Indirect
Feb 16, 2024Common StockSSaleDisposed−162,707$23.14F5−$3,765,039.986,985,504Indirect
Feb 20, 2024Common StockSSaleDisposed−166,029$22.71F6−$3,770,518.596,819,475Indirect
Feb 20, 2024Common StockSSaleDisposed−3,510$23.40F7−$82,1346,815,965Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.40 to $24.3943 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (4), (5), (6) and (7).

Referenced by the price of 1 transaction in Table I.

F4

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.40 to $24.51 inclusive.

Referenced by the price of 1 transaction in Table I.

F5

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.878 to $23.54 inclusive.

Referenced by the price of 1 transaction in Table I.

F6

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.117 to $23.09 inclusive.

Referenced by the price of 1 transaction in Table I.

F7

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.16 to $24.01 inclusive.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)